Biosimilar uptake was greater in Medicare Advantage plans when compared with traditional Medicare plans.
A cross-sectional study, published on the JAMA Health Forum, found biosimilar use and market share higher in Medicare Advantage (MA) plans compared with traditional Medicare (TM) plans for most biosimilar products, except for bevacizumab.
Calculated cumulative data from May 2015 to September 2022 was used to evaluate biosimilar market shares for products with at least 1 biosimilar administration on or before September 30, 2019. A total of 20 biosimilar products were included, mainly used in Parts B and C, amongst 7 different product types.
Product types included infliximab, epoetin alfa, bevacizumab, pegfilgrastim, filgrastim, rituximab, and trastuzumab. Each product recorded a cumulative percentage market share from biosimilar introduction and throughout the 36 weeks following introduction. Market share was defined as the number of biosimilar administrations of the total administrations of biosimilars and their reference products.
As of January 2024, the FDA has approved 5 bevacizumab biosimilars, 4 infliximab biosmilars, 1 epoetin alfa biosimilar, 3 rituximab and filgrastim biosimilars each, 5 trastuzumab biosimilars, and 6 pegfilgrastim biosimilars.
Vegzelma (bevacizumab-adcd), Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Alymsys (bevacizumab-maly), and Avzivi (bevacizumab-tnjn) are the brand names for the bevavizumab biosimilars. Renflexis (infliximab-abda), Avsola (infliximab-axxq), Inflectra (infliximab-dyyb), and Ixifi (infliximab-qbtx) represent the approved infliximab biosimilars. Retacrit (epoetin alfa-epbx) is the only epoetin alfa biosimilar. Zarxio (filgrastim-sndz), Nivestym (filgrastim-aafi), and Releuko (filgrastim-ayow) are the filgrastim biosimilar products. Truxima (rituximab-abbs), Riabni (rituximab-arrx), and Ruxience (rituximab-pvvr) make up all the rituximab biosimilars. Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst), Ontruzant (trastuzumab-dttb), Herzuma (trastuzumab-pkrb), and Trazimera (trastuzumab-qyyp) all reference Herceptin (trastuzumab). Lastly, Nyvepria (pegfilgrastim-apgf), Ziextenzo (pegfilgrastim-bmez), Udenyca, (pegfilgrastim-cbqv), Stimufend (pegfilgrastim-fpgk), Fulphila - (pegfilgrastim-jmdb) and Fylnetra (pegfilgrastim-pbbk). In January, the on-body injector version of Udenyca was approved to compete against Neulasta Onpro (on-body injector reference pegfilgrastim).
Out of 6 of the 7 product types, results showed that MA plans had greater biosimilar uptake than TM plans. MA plans had 1.1 and 2.3 times greater uptake for trastuzumab and epoetin alfa biosimilars, respectively, compared with TM plans. All 7 products had a 1.3 (range, 0.7-2.3) median ratio for both MA and TM, with a median difference of 5.7% (range, –4.48% to 9.43%).
However, the products producing the least amount of biosimilar market share differed between MA and TM. For epoetin alfa biosimilars, MA had 5.7% times greater uptake than TM. Bevacizumab biosimilars had the lowest biosimilar market share for MA, with a –4.48% percentage point difference between plan types.
The indicator for bevacizumab was divided into ophthalmic vs oncologic usage. Although the reference product (Avastin) is only indicated for oncology use, it is often prescribed off-label for neovascular age-related macular degeneration. In the ophthalmic group, bevacizumab biosimilars had very low market share. However, market share was higher in TM plans than MA plans.
Data for epoetin alfa biosimilars, which originally had 2 times greater market share in MA plans than TM plans was stratified by end-stage kidney disease (ESKD) and non-ESKD utilization. Like other product types, epoetin alfa biosimilars had 1.5 to 1.7 times greater uptake in MA plans than TM plans. Combining uptake for ESKD and non-ESKD indications resulted in a higher relative weighting of MA biosimilar use.
Study limitations included the potential differences in population characteristics amongst MA and TM. The implementation of the Medicare inflationary rebate could also affect the biosimilar use and market share percentages of MA or TM.
The authors suggested that additional studies should incorporate all avenues of clinical indications. The authors concluded, “Thus, it is important to validate the increased biosimilar uptake observed in MA and investigate potential mechanisms through which managed care may encourage greater biosimilar use.”
Reference:
Kozlowski S, Kwist A, McEvoy R, et al. Biosimilar uptake in medicare advantage vs traditional medicare. JAMA Health Forum. 2023;4(12):e234335. doi:10.1001/jamahealthforum.2023.4335
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.